At all stagesof MS, including during clinical attacks, lytic-specific CD8+ Tcells were decreased in the PBMC (Figure 3a), with thefrequencies of lytic-specific CD8+ T cells, CD8+EM T cells, CD8+ EMRA T cells and CD8+ EM/EMRAT cells all being significantly lower than in healthy subjects (Figure 3b). This evidence concerns the gene CD8A and myeloid sarcoma.